Improved Medically Assisted Procreation (MAP) Monitoring
Improved Medically Assisted Procreation (MAP) Monitoring
Patient care in Medically Assisted Procreation (MAP) requires a close and regular monitoring of the evolution of the estradiol rate. This monitoring allows the dose and duration of treatment to be accurately adjusted for each woman (every 24 or 48 hours) up to 10 to 15 days of treatment with gonadotrophins. Oestradiol (E2) is secreted by the growing ovarian follicles and reflects their growth and maturity. Its plasma dosage makes it possible to monitor the ovarian response to stimulation.
This monitoring involves several constraints amongst which disruption of work life, stress, fatigue that can alter the response to treatment
In order to improve the comfort of patients already under severe stress, simplification of this monitoring is proposed. The development of an immediate-release whole blood test for simplified monitoring of estradiol levels will provide considerable comfort in the management of patients. These patients are subjected to significant emotional and physical stress and the development of this test will reduce the negative consequences that result.
Inclusion criteria:
Exclusion Criteria:
cela.ravel@chu-rennes.fr+3332 99 26 59 16